• Feb4

    Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

    RUTHERFORD, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the closing and funding of its previously announced public offering of 15,217,392 shares of its common stock (“Common Stock”) at a public offering price […]

    » Continue Reading

  • Feb4

    Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock

    RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of a public offering of 15,217,392 shares of its common stock, offered at a price to the public of $0.23 per share, […]

    » Continue Reading

  • Feb4

    Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

    RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering […]

    » Continue Reading

  • Jan16

    Cancer Genetics Issues Letter to Shareholders

    RUTHERFORD, N.J., Jan. 16, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today published a letter to shareholders from its Chief Executive Officer, Jay Roberts. Dear Shareholders, Happy New Year – we are pleased to provide an update […]

    » Continue Reading

  • Jan15

    Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

    RUTHERFORD, N.J., Jan. 14, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the closing and funding of its previously announced underwritten public offering of 13,333,334 shares of its common stock (“Common Stock”) at a public offering […]

    » Continue Reading

  • Jan10

    Cancer Genetics, Inc. Announces Pricing of Public Offering of Common Stock

    RUTHERFORD, N.J., Jan. 09, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $0.225 per share. […]

    » Continue Reading

  • Jan9

    Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

    RUTHERFORD, N.J., Jan. 09, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Cancer […]

    » Continue Reading

  • Jan9

    Cancer Genetics Strengthens Management Team with Appointment of William Finger as Executive Vice President, Precision Medicine and Pharma Services

    Executive appointment underscores continued execution of new corporate strategy of expanding Biopharma and Discovery businesses  RUTHERFORD, N.J. and RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of William Finger […]

    » Continue Reading

  • Dec17

    Cancer Genetics Terminates Proposed Merger with NovellusDx

    RUTHERFORD, N.J., Dec. 17, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it has terminated the previously-announced merger agreement with NovellusDx, effective immediately. As a result of the termination of the merger agreement, the Company will […]

    » Continue Reading

  • Nov14

    Cancer Genetics Appoints Glenn Miles as Chief Financial Officer

    RUTHERFORD, N.J., Nov. 14, 2018 (GLOBE NEWSWIRE) — Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of Glenn Miles as Chief Financial Officer, effective November 26, 2018. Additionally, Mr. Igor Gitelman, Chief Accounting Officer of the Company will be departing […]

    » Continue Reading

  • Oct18

    Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin® Test in China

    RUTHERFORD, N.J., Oct. 18, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed an exclusive distribution agreement with Genecast Biotechnology to market, distribute and sell the Tissue of Origin® (TOO) Test in China. John A. […]

    » Continue Reading

  • Oct16

    Cancer Genetics Issues Letter to Shareholders

    RUTHERFORD, N.J., Oct. 16, 2018 (GLOBE NEWSWIRE) — Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the publication of a letter to shareholders from its Chief Executive Officer Jay Roberts. Dear Shareholders, As we approach the last few months of 2018, it […]

    » Continue Reading

  • Oct8

    Cancer Genetics and Cellaria Partner on Precision Medicine Tools

    Collaboration focused on developing pharmacology models to support biopharma R&D RUTHERFORD, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) — Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, and Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models, today announced a new collaboration to […]

    » Continue Reading

  • Sep26

    Cancer Genetics Enters Supply Agreement with Agilent Technologies

    Probes for CGI’s FISH-based HPV-Associated Cancer Test (FHACT®) test to be manufactured by Agilent RUTHERFORD, N.J., Sept. 25, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed a non-exclusive supply agreement with Agilent Technologies […]

    » Continue Reading

  • Sep20

    Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials

    RUTHERFORD, N.J., Sept. 20, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the successful CLIA validation and commercial launch of Thermo Fisher Scientific’s next-generation sequencing (NGS) Oncomine™ Comprehensive Assay v3 for biopharma clinical trials. John A. Roberts, […]

    » Continue Reading

  • Sep18

    Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

    Transaction to Create a Leader in Precision Oncology RUTHERFORD, N.J. and JERUSALEM, Sept. 18, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and NovellusDx, Ltd., a leader in functional genomics, today announced the signing of a definitive agreement […]

    » Continue Reading

  • Aug14

    Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates

    Conference call at 8:30 a.m. ET, Tuesday, August 14, 2018 RUTHERFORD, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced financial and operating results for the second quarter ended June 30, 2018 as well […]

    » Continue Reading

  • Aug7

    Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018

    Conference call at 8:30 a.m. EDT, Tuesday, August 14, 2018 RUTHERFORD, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the second quarter ended June 30, 2018 on Tuesday, August […]

    » Continue Reading

  • Jul18

    Cancer Genetics Closes $2.625 million Convertible Note Financing

    RUTHERFORD, N.J., July 18, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the closing of a $2.625 million convertible note financing with a single institutional investor. John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “This capital raise helps […]

    » Continue Reading

  • Jun12

    Cancer Genetics Strengthens Management Team with Appointment of Michael McCartney as Chief Commercial Officer

    Executive appointment underscores continued execution of new corporate strategy of expanding Biopharma and Discovery businesses RUTHERFORD, N.J., June 12, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the appointment Michael McCartney as the Company’s Chief Commercial Officer, effective immediately. Mr. […]

    » Continue Reading